New Drug Rules On Licensing, Trials, Surveillance Edge Closer In Singapore

This article was originally published in SRA

18 Feb 2016
News

Neena Brizmohun @ScripRegNeena neena.brizmohun@informa.com

Executive Summary

Pharmaceutical companies doing business in Singapore are being advised to review the procedures they have in place relating to drug licensing, conducting clinical trials and responding to post-market surveillance in light of proposed legislative changes in the country.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS118549

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS118549

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

New Drug Rules On Licensing, Trials, Surveillance Edge Closer In Singapore

News

Executive Summary

Related Content

Singapore: Less Than Three Months Left For Companies To Prepare For New Pharma Rules

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert